Systematic review of long-term chemotherapy-induced peripheral neuropathy (CIPN) following adjuvant oxaliplatin for colorectal cancer

[1] André T(2004)Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer N Engl J Med 350 2343-2351

[2] Boni C(2015)Clinical course of oxaliplatin-induced neuropathy: results from the randomized phase III trial N08CB (Alliance) J Clin Oncol 33 3416-3422

[3] Mounedji-Boudiaf L(2021)Impact of adjuvant therapy toxicity on quality of life and emotional symptoms in patients with colon cancer: a latent class analysis Clin Transl Oncol 23 657-662

[4] Navarro M(2019)Long-term neuropathy and quality of life in colorectal cancer patients treated with oxaliplatin containing adjuvant chemotherapy Acta Oncol 58 398-406

[5] Tabernero J(2018)The incidence of acute oxaliplatin-induced neuropathy and its impact on treatment in the first cycle: a systematic review BMC Cancer 18 410-4777

[6] Hickish T(2017)The experience of chemotherapy-induced peripheral neuropathy in adult cancer patients: a qualitative thematic synthesis Eur J Cancer Care (Engl) 26 e12443-716

[7] Topham C(2019)Chemotherapy-induced peripheral neuropathy-patient-reported outcomes compared with NCI-CTCAE grade Support Care Cancer 27 4771-181

[8] Zaninelli M(2021)The PRISMA 2020 statement: an updated guideline for reporting systematic reviews BMJ 372 n71-611

[9] Clingan P(2003)Methodological index for non-randomized studies (MINORS): development and validation of a new instrument ANZ J Surg 73 712-1581

[10] Bridgewater J(2003)CTCAE v3.0: development of a comprehensive grading system for the adverse effects of cancer treatment Semin Radiat Oncol 13 176-578

[1] André T(2004)Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer N Engl J Med 350 2343-2351

[2] Boni C(2015)Clinical course of oxaliplatin-induced neuropathy: results from the randomized phase III trial N08CB (Alliance) J Clin Oncol 33 3416-3422

[3] Mounedji-Boudiaf L(2021)Impact of adjuvant therapy toxicity on quality of life and emotional symptoms in patients with colon cancer: a latent class analysis Clin Transl Oncol 23 657-662

[4] Navarro M(2019)Long-term neuropathy and quality of life in colorectal cancer patients treated with oxaliplatin containing adjuvant chemotherapy Acta Oncol 58 398-406

[5] Tabernero J(2018)The incidence of acute oxaliplatin-induced neuropathy and its impact on treatment in the first cycle: a systematic review BMC Cancer 18 410-4777

[6] Hickish T(2017)The experience of chemotherapy-induced peripheral neuropathy in adult cancer patients: a qualitative thematic synthesis Eur J Cancer Care (Engl) 26 e12443-716

[7] Topham C(2019)Chemotherapy-induced peripheral neuropathy-patient-reported outcomes compared with NCI-CTCAE grade Support Care Cancer 27 4771-181

[8] Zaninelli M(2021)The PRISMA 2020 statement: an updated guideline for reporting systematic reviews BMJ 372 n71-611

[9] Clingan P(2003)Methodological index for non-randomized studies (MINORS): development and validation of a new instrument ANZ J Surg 73 712-1581

[10] Bridgewater J(2003)CTCAE v3.0: development of a comprehensive grading system for the adverse effects of cancer treatment Semin Radiat Oncol 13 176-578